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Abstract
The A allele of a common A-T polymorphism in the sig-
nal peptide of ·1-antichymotrypsin gene (ACT) has been
reported to contribute a two- to threefold increased risk
to Alzheimer’s disease (AD) patients who carry the apoli-
poprotein E Â4 (APOE Â4) genotype. Since the ACT
expression in AD brains is enhanced in particular in
areas that develop amyloid plaques, the ACT polymor-
phism is considered to be a good candidate gene. We
have analyzed this polymorphism in 102 AD patients and
191 matched controls, all originating from Western Ger-
many. No statistically significant differences in allele fre-
quencies and in genotype distribution of ACT could be
shown between AD patients and controls. When we ana-
lyzed the polymorphism in APOE Â4 carriers, no overre-
presentation in our AD group could be shown for the
ACT*AA genotype carriers.
Copyright © 1999 S. Karger AG, Basel
Introduction
Alzheimer’s disease (AD) is a genetically heteroge-
neous neurodegenerative disorder that is the most fre-
quent cause of dementia in the elderly. It is well estab-
lished that early-onset forms of AD often show an autoso-
mal dominant pattern of inheritance which is mainly due
to mutations in the amyloid precursor protein (APP), pre-
senilin 1 (PS1) or presenilin 2 gene (PS2) [1]. In contrast,
the more common late-onset and sporadic forms of AD
exhibit a more complex pattern of inheritance. In the last
5 years apolipoprotein E Â4 (APOE Â4) has been well
established as a major risk factor [1]. Most recently it has
been suggested that ·2-macroglobulin is associated with
late-onset AD [2]. In addition, there may be other genes
acting independently or interactively in the pathogenesis
of the disease. One candidate gene that might play a role
in the development of the disease is ·1-antichymotrypsin
(ACT). In the filamentous deposits found in brains of AD
patients ACT binds to ß-amyloid peptide with high affini-
ty. Thus it is thought that ACT serves as a strong activat-
ing factor in the polymerization of ß-amyloid peptide into
amyloid filaments [3, 4].
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Table 1. Comparison of ACT genotype and allele frequency in AD
patients and controls
Genotype1 AD patients (n = 102) Controls (n = 191)
52 (51%) 115 (60.2%)
ACT*AA 30 (29.4%) 46 (24.1%)
ACT*TT 20 (19.6%) 30 (15.7%)
Allele frequency
ACT*A 0.549 0.542
ACT*T 0.451 0.458
1 ¯2 = 2.3; d.f. = 2; p = 0.32.
Table 2. ACT genotypes dependent on APOE Â4 genotypes in AD
patients and controls
Genotype AD patients
n %
Controls
n %
ACT*AT 24 60.0 84 59.2
ACT*AA 13 32.5 36 25.4
ACT*TT 3 7.5 22 15.4
APOE Â4 carrier2
ACT*AT 28 45.2 31 63.3
ACT*AA 17 27.4 10 20.4
ACT*TT 17 27.4 8 16.3
APOE Â4 noncarriers: 40 AD patients, 142 controls. APOE Â4
carriers: 62 AD patients, 49 controls.
1 ¯2 = 2.1; d.f. = 2; p = 0.36.
2 ¯2 = 3.7; d.f. = 2; p = 0.16.
Kamboh et al. [5] were the first to report an association
between a common polymorphism in the signal peptide of
ACT and APOE Â4 carriers with AD. On the background
of controversial results on association of ACT concerning
the German population, it was our intention to analyze
this polymorphism together with the APOE polymor-
phism in a German sample of 102 sporadic, late-onset AD
patients and 191 controls. Patients and controls were
recruited from the general population. No association
between ACT*A allele neither in APOE Â4 carriers nor in
our total AD group was detected.
Material and Methods
Patients
AD patients were recruited from the outpatient memory disorder
clinic of the Psychiatric Department of the University of Bonn. Diag-
nosis of probable AD was performed by standard clinical evaluation
according to NINCDS-ADRDA criteria. Medical and family history,
general medical and neurological examination, psychiatric interview,
neurological testing, blood and cerebrospinal fluid studies as well as
CT scans were carried out to exclude other forms of dementia. Alto-
gether 102 AD patients were included in this study. The mean age
was 74.4 years (range 51–101 years), 68 of them were female and 34
male patients. Patients with familial (autosomal-dominant) AD were
not included.
Controls
Supported by the local Census Bureau and the regional Board of
Data Protection (Nordrhein-Westfalen, Germany) a random sample
of subjects over 50 years was selected from the general population.
The control group comprised 191 nondemented subjects. They were
evaluated based upon a psychiatric interview and neurological test-
ing. Mean age was 70.6 years (range 50–100 years), 99 were female
and 92 male subjects. Informed consent was obtained for all patients
and controls.
Genotyping
DNA was extracted from whole blood using Quiagen Blood DNA
Kit (Quiagen, Hilden, Germany). The APOE polymorphism was
analyzed by a PCR-based method as described by Hixon and Vernier
[6]. The ACT polymorphism also was analyzed by a PCR-based
method as described by Kamboh et al. [5].
Statistical Analysis
¯2 distribution and Fisher’s exact test were used for analysis of the
data. Power calculations were carried out using arcsine transforma-
tions of percentages as proposed by Lipsey [7].
Results
Altogether 102 AD patients and 191 matched controls
were genotyped for the ACT polymorphism and the
APOE polymorphism. Hardy-Weinberg equilibrium
could be demonstrated for both polymorphisms in pa-
tients and controls. ACT was first analyzed neglecting the
APOE genotype. Kamboh et al. [5] reported an increased
risk for carriers of the ACT*AA genotype. In our analysis
the ACT*AA genotype was detected in 30 patients
(29.4%) and in 46 controls (24.1%); 20 AD patients
(19.6%) and 30 controls (15.7%) carried the ACT*TT
genotype. This difference was statistically not significant
(¯2 = 2.3; d.f. = 2, p = 0.32, table 1). Breakdown of the
samples according to age and sex had no influence on this
distribution (data not shown).
Since an increased risk was reported for ACT*AA car-
riers that in addition carry the APOE Â4 genotype we
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grouped the AD patients and controls in individuals
carrying the APOE Â4 genotype or not. Thirteen patients
(32.5%) and 36 controls (25.4%) without APOE Â4 allele
were homozygous for ACT*A, 3 patients (7.5%) and 22
controls (15.4%) were homozygous for ACT*T. Seventeen
patients (27.4%) and 10 controls (20.4%) among the car-
riers of the APOE Â4 allele had an ACT*AA genotype
while 17 AD patients (27.4%) and 8 controls (16.3%)
showed an ACT*TT genotype. These data did not reach
any statistical significance when Fisher’s exact test was
applied. For the APOE Â4 noncarriers a p value of 0.36
and for the APOE Â4 carriers, a p value of 0.16 was
obtained (table 2).
Power calculations revealed a statistical power of 72%
to detect an effect of the size originally reported by Kam-
boh et al. [5].
Discussion
In the present study we could not observe a significant
influence of the ACT genotype on the risk of AD. After
the first report on a modification of an APOE Â4-associat-
ed risk for AD by ACT [5] a number of contradictory
results have been published. Yoshiiwa et al. [8] replicated
the original finding in a Japanese population, Thome et
al. [9] in a German population, Ezquerra et al. [10], work-
ing with a Spanish population, could only replicate the
finding in non-APOE Â4 carriers. Nacmias et al. [11]
obtained some hint that ACT may interact with APOE in
their late-onset familial AD cases. In 1997, Kamboh et al.
[12] also reported a gender-specific effect. However, most
groups could not replicate the finding even if they break
down their samples according to sex and age [13–23].
Power calculations showed that the statistical power of
our sample to detect the originally reported differences in
the distribution of the ACT polymorphism between AD
patients and healthy subjects stratified by the presence or
absence of the APOE Â4 allele was 72%. In context with
the other negative results reported in the literature [13–
23] we conclude that the ACT genotype might have no or
only a minor effect on AD risk in our population.
Moreover, results of association studies using a case-
control design are explicitly sensitive to stratification. In
AD it is almost impossible to perform family-based asso-
ciation studies. In order to circumvent stratification prob-
lems, we used a sample that was carefully matched for age,
gender and ethnicity.
When we assume genetic heterogeneity between differ-
ent populations, we cannot exclude that ACT may have
an effect on AD risk in some populations. However,
regarding all the contradictory results, this effect, if
present, might be a very minor one.
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